Summit Therapeutics
SMMTSMMT · Stock Price
Historical price data
Overview
Summit Therapeutics' mission is to develop and commercialize innovative medicines for serious unmet medical needs, with a strategic focus on oncology and infectious diseases. Its key achievement is the advancement of ivonescimab, a novel bispecific antibody targeting PD-1 and VEGF, into pivotal Phase III trials for non-small cell lung cancer (NSCLC). The company's strategy combines strategic asset acquisition with focused clinical development to build value through high-potential, late-stage programs. Summit's significant market valuation reflects investor confidence in its lead asset's differentiated profile and blockbuster potential.
Technology Platform
Strategic asset development platform focused on advancing novel, differentiated biologic mechanisms, exemplified by the bispecific antibody ivonescimab which co-targets PD-1 and VEGF within a single molecule.
Pipeline
27| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Ridinilazole + Vancomycin | Clostridioides Difficile Infection | Phase 3 | |
| Drug: Ivonescimab Injection + Drug: Bevacizumab Injection | Metastatic Colorectal Cancer (CRC) | Phase 3 | |
| Ivonescimab Injection + Pembrolizumab Injection | Non-Small Cell Lung Cancer | Phase 3 | |
| Ridinilazole + Vancomycin | Clostridioides Difficile Infection | Phase 3 | |
| Ivonescimab Injection + Pembrolizumab Injection | Non-Small Cell Lung Cancer | Phase 3 |
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Ivonescimab competes in crowded lung cancer markets dominated by blockbuster PD-(L)1 inhibitors from Merck, BMS, and Roche. Its success depends on demonstrating clear efficacy/safety advantages over standard combination therapies. As a potential first-in-class PD-1/VEGF bispecific, it holds a first-mover advantage against earlier-stage competitive molecules.